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! We report the largest series to our knowledge of PCR-proven autochthonous acute 
hepatitis E. 
! Middle-aged and elderly men constitute the majority of symptomatic patients, with 
particularly severe courses in patients with underlying chronic liver disease. 
! Most infections were due to hepatitis E virus of genotype 3, with limited clusters 
identified by phylogenetic analyses; three cases of genotype 4 infection acquired in 
Switzerland were also documented. 
! Testing for HEV should be included early in the diagnostic workup of acute hepatitis and 




Background: Autochthonous hepatitis E is increasingly recognized as zoonotic infection in 
western countries. Serologic assays have varying sensitivity and specificity. 
Methods: We implemented molecular testing to identify and characterize acute hepatitis E 
acquired in Switzerland. 
Results: Ninety-three cases of mostly symptomatic acute hepatitis E acquired in Switzerland 
were documented by PCR between November 2011 and December 2016. Median HEV RNA 
was 7.5 x 104 IU/ml (range, 5.3 to 4.7 x 107 IU/ml). HEV genotyping was successful in 78 
patients, revealing genotype 3 in 75 and genotype 4 in 3 patients. Phylogenetic analyses 
revealed a few limited geographial and temporal clusters. Of the 91 patients with available 
anti-HEV IgM serology, 4 were negative; three of these were also IgG-negative, likely as a 
result of immunosuppression, and one was IgG positive, a constellation compatible with HEV 
reinfection. Median age of the patients was 58 years (range, 20-80 years); 71 (76.3%) were 
men and 49 of these (69.0%) were ≥ 50 years old. The clinical course was particularly severe 
in patients with underlying chronic liver disease, with fatal outcome in two patients. Six 
patients (6.5%) presented with neuralgic amyotrophy. 
Conclusions: Nucleic acid-based diagnosis reveals HEV as a relevant cause of acute 
hepatitis in Switzerland. Middle-aged and elderly men constitute the majority of symptomatic 
patients. Testing for HEV should be included early in the diagnostic workup of acute hepatitis 
and of neuralgic amyotrophy, a typical extrahepatic manifestation of HEV genotype 3 
infection. 
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1 | INTRODUCTION 
Hepatitis E virus (HEV) is believed to be the most common cause of acute hepatitis and 
jaundice in the world.1, 2 It is a positive-strand RNA virus classified in the Hepeviridae family.3 
Two scenarios have been described: On the one hand, HEV genotypes 1 and 2 cause 
waterborne outbreaks mainly in the developing world, infecting about 20 million people and 
claiming 70,000 lives every year.4 On the other hand, HEV genotypes 3 and 4 have been 
recognized as zoonotic infections in the developed world, with much higher than anticipated 
seroprevalence rates, reaching 86.4% in the Southwest of France.5 
HEV genotype 3 has a worldwide distribution while genotype 4 has been found mainly in 
China and Southeast Asia (refs. 3 and 6 as well as references therein). Both infect humans 
as well as swine, wild boar, deer and other animal species. Transmission to humans is 
believed to occur mainly through the consumption of raw or undercooked meat but other 
routes of transmission have been suggested.7, 8 
The prevalence of anti-HEV IgG in Switzerland has been reported to range between 4.2 
and 21.8%, depending on the serologic assay used.9, 10 This broad range points to the 
varying sensitivity and specificity of currently available serologic assays for hepatitis E, as 
documented in other studies.11, 12. In addition, the epidemiological, virological and clinical 
features of HEV infection acquired in Switzerland have not been described. On this 
background, we explored molecular testing for HEV infection to characterize acute hepatitis 
E acquired in Switzerland. 
 
2 | PATIENTS AND METHODS 
2.1 | Patients 
Molecular testing for HEV at the University Hospital Lausanne has been offered to the Swiss 
medical community since November 2011. Samples were sent in a context of diagnostic 
workup for mostly symptomatic hepatitis. Demographic characteristics as well as clinical and 
laboratory data from all patients with a positive PCR result for HEV RNA were collected. The 
study was approved by the Ethical Committee of the Canton de Vaud, Switzerland (protocol 
no. 478/15). The Swiss law and acts on research involving human beings allow performing 
retrospective studies without consent in exceptional cases. Our study was approved by the 
Ethical Committee under these circumstances since (i) the interest of research was 
considered to outweigh the interest of the persons and (ii) obtaining consent was considered 
disproportionately difficult. Patients with a travel history to a classical endemic area in the 
preceding 3 months and immunocompromised individuals with chronic hepatitis E were 
excluded from the present analysis. 
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The following items were recorded: age and gender, travel history in the 3 months 
preceding the diagnosis of hepatitis E, history of underlying chronic liver disease or 
immunosuppression, results of anti-HEV IgM and IgG assays, peak alanine 
aminotransferase (ALT), presence or absence of jaundice and, in patients with jaundice, 
peak bilirubin levels. Serologic assays were performed locally in the centers that then sent 
the samples for molecular testing. Samples from patients whose initial diagnostic workup did 
not include anti-HEV serology and for whom sufficient material was available (n = 6) and 
those who were reported to be anti-HEV IgM-negative (n = 5), were (re)tested centrally using 
the assays from Dia.Pro Diagnostic Bioprobes (Milan, Italy). 
 
2.2 | Quantitative PCR and genotyping 
Purification of nucleic acids and reverse transcription were performed as described in the 
Supplementary Material, followed by real-time polymerase chain reaction according to 
Jothikumar et al.,13 with the updated primer set and reaction conditions listed in 
Supplementary Table 1. Each set of RNA extractions was accompanied by a negative water 
control to monitor contamination. The PCR assay showed excellent sensitivity and specificity 
as well as performance in a European validation panel, as detailed in the Supplementary 
Material. The international standard received from the Paul Ehrlich Institute in Langen, 
Germany (ref. 14; PEI code 6329/10; version 1.0; July 7, 2011) was used to quantify results. 
HEV genotype was determined by sequencing of touch down PCR amplicons 
encompassing the open reading frame (ORF) 2/3 region of the viral genome 
(Supplementary Table 1). Primer sequences were removed prior to phylogenetic analysis of 
the resulting 191-195-bp fragments by neighbor-joining tree building with the integrated 
Geneious version 10.0.5 or superior bioinformatic analysis tool (ref. 15; 
https://www.geneious.com). The 310 full-length HEV sequences available on September 1, 
2016 were retrieved from GenBank and clustered to at least 85% nucleotide homology. The 
40 resulting contigs, representing at least 4 genomes each, were used as references in tree 
building, after trimming to the internal amplicon region defined by primers HEVgenF-H and 
HEVgenR-A (Supplementary Table 1). Phylogenetic analysis was performed with MrBayes16 
using standard parameters for DNA in the Geneious software. HEV of a subset of patients 
was also genotyped with a PCR protocol amplifying a 595-bp fragment from the ORF2 region 
recommended for HEV genotyping (refs. 17 and 18 as well as Supplementary Material). 
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3 | RESULTS 
A total of 1981 samples were sent for diagnostic PCR testing between November 2011 and 
December 2016, the majority for symptomatic hepatitis, with a continuous increase over the 
years (Figure 1A). Of these, 145 (7.3%) samples from 111 patients were positive for HEV 
RNA. 
Demographic, clinical and laboratory data was obtained for 110 patients (Figure 1B). Of 
these, 8 had recently traveled to Asia and were excluded from the present analysis (7 HEV 
genotype 1 infections acquired in the Indian subcontinent and one HEV genotype 4 infection 
likely acquired in China). Moreover, we also excluded 9 cases of chronic hepatitis E of which 
7 were documented in liver transplant recipients, one in a kidney transplant recipient and one 
in a bone marrow transplant recipient. Hence, data from 93 patients with acute hepatitis E 
likely acquired in Switzerland were included in the present analysis (Supplementary Table 2). 
Median HEV RNA was 7.5 x 104 IU/ml (range, 5.3 to 4.7 x 107 IU/ml). HEV genotyping 
with the ORF2/3-based assay was successful in 78 patients, revealing infection with 
genotype 3 in 75 and with genotype 4 in three. HEV genotyping was unsuccessful in 15 
patients of which the majority had low viral titers. 
Phylogenetic tree analysis of the identified HEV genotype 3 and 4 sequences is shown in 
Figure 2A. All nodes to the genotypic levels were supported by a high posterior probability 
(pb), as denoted by an asterisk (HEV genotype 1: pb = 1; genotype 4: pb = 1; genotype 3: pb 
= 0.98). Phylogenetic analyses, although not always robust, revealed a few limited 
geographical and temporal clusters according to Canton of residence (Figure 2B) and year of 
acute hepatitis E. For example, patients 24, 30 and 32, who were infected with a closely 
related virus (pb = 0.74), all resided in the Canton Ticino and developed acute hepatitis E 
within a 6-month interval. As another example, the viral strains isolated from patients 81, 86 
and 89 (pb = 1) showed a similar geographical clustering within a 20-km range and a 2-
month interval. These clusters were further confirmed with the ORF2-based genotyping 
assay (data not shown). 
Several patients with distinct clinical outcomes were under the same highly supported 
phylogenetic node (e.g. patients 35 and 43 with neuralgic amyotrophy and death due to 
acute-on-chronic liver failure, respectively; pb = 1). Conversely, patients presenting with 
similar clinical outcomes were distributed under different nodes (e.g. patients 8 and 35 as 
well as 14, 46, 47 and 68 with neuralgic amyotrophy). These data are consistent with a lack 
of association of specific HEV genotype 3 strains with defined clinical outcomes. 
7 
The three genotype 4 infections were all observed in the northeastern part of Switzerland. 
Seasonal variation of the number of submitted samples or the percentage of positive 
samples was not evident (data not shown). 
Results of anti-HEV IgM testing were available in 91 patients and results of both anti-HEV 
IgM and IgG in 90. Of the latter, 7 (7.8%) were positive for anti-HEV IgM but negative for IgG, 
79 (87.8%) were positive for both anti-HEV IgM as well as IgG, and one was negative for 
anti-HEV IgM but positive for IgG. Three patients were negative for both anti-HEV IgM and 
IgG: one had received chemotherapy and rituximab for lymphoma 7 months prior to acute 
hepatitis E, one was a renal transplant recipient and one was treated with predisone 20 mg 
per day for pulmonary fibrosis. Hence, of the 91 patients with available anti-HEV IgM 
serology, 4 were negative. Three of these were also IgG-negative, likely as a result of 
immunosuppression, and one was IgG positive, a constellation compatible with HEV 
reinfection. 
Seventy-one of the 93 patients (76.3%) were men. Median age of all patients was 58 
years, with a range between 20 and 80 years and an interquartile range between 47 and 69 
years. Sixty-three of all patients (67.7%) and 49 of male patients (69.0%) were ≥ 50 years 
old. 
Fourty-nine patients (52.7%) presented with jaundice. In this setting, peak total bilirubin 
ranged between 45 and 602 µmol/l (median 120 µmol/l). In the absence of jaundice, PCR 
testing for HEV RNA was generally motivated by flu-like symptoms, including myalgia, 
arthralgia and low-grade fever, or by neurologic symptoms (see below) associated with 
elevated ALT levels. Median peak ALT was 1378 U/l, with a wide range between 80 and 
5001 U/l. 
The clinical course was particularly severe in patients with underlying chronic liver 
disease. Four patients experienced decompensation of pre-existing cirrhosis, with ascites, 
hepatorenal syndrome and/or hepatic encephalopathy, but ultimately recovered with 
supportive treatment. However, two patients with underlying cirrhosis developed acute-on-
chronic liver failure with a fatal outcome. They were 80 and 74 years old, respectively, 
presented initially with deep jaundice as well as ascites and subsequently developed renal 
failure and hepatic encephalopathy. Alcoholic hepatitis was initially suspected in both 
patients. Ribavirin was started upon documentation of HEV infection, 5 days before death in 
the first and one day before death in the second patient. 
Drug-induced liver injury was initially suspected in at least two patients (liraglutide for 
diabetes in patient 8 and erlotinib for lung cancer in patient 9; Supplementary Table 2). 
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Six of the 93 patients (6.5%) presented with bilateral, asymmetric neuralgic amyotrophy 
(also known as brachial neuritis or Parsonage-Turner syndrome). All of these were men 
infected with HEV genotype 3. Their median age was 50 years, with a narrow range between 
45 and 62 years. Peak ALT levels in these patients ranged from 99 to 2579 U/l; only two 
developed jaundice. Neurological manifestations have been reported in refs. 19 and 20. One 
patient was treated with prednisone and ribavirin. The others were treated with 
corticosteroids and/or intravenous immunoglobulins according to local expertise. The 
outcome was overall favorable in all patients, with resolution of neuralgic pain. However, 
minor motor deficits persisted in the majority as per their last control exam performed up to 
> 2 years after the acute episode. 
 
4 | DISCUSSION 
We successfully implemented nucleic acid-based diagnosis of hepatitis E. Between 
November 2011 and December 2016 we observed a steady increase in demand for 
molecular testing, likely reflecting enhanced awareness for hepatitis E in the Swiss medical 
community, although a true increase in the incidence of HEV infection and/or the number of 
symptomatic cases cannot be excluded, as also discussed in a recent study addressing the 
risk of foodborne HEV transmission in Switzerland.21 The proportion of positive samples 
remained roughly constant over the years, allowing us to characterize 93 patients with acute 
hepatitis E acquired in Switzerland. Samples for molecular testing were sent by physicians 
across Switzerland mostly in a context of diagnostic workup for symptomatic acute hepatitis. 
In 2016, one new patient with acute hepatitis E was identified every 9 days, i.e. almost every 
week. 
To the best of our knowledge, this is the largest series so far to evaluate PCR-proven 
acute hepatitis E. Indeed, most of the published studies are based on serological assays. 
However, serological tests for anti-HEV IgM and IgG have varying sensitivity and 
specificity.10-12 Nijskens et al. recently reported 79 patients with HEV genotype 3 infection 
from the Netherlands.22 Kokki et al. reported 39 patients with PCR-proven acute hepatitis E 
from Scotland.23 
It is important to note that some samples sent for testing may have been PCR-negative 
because they were sent after the window of PCR positivity. In fact, it is currently believed that 
HEV RNA is cleared from serum or plasma within an average of 3 weeks after the 
appearance of symptoms.24, 25 Hence, molecular and serological testing may be regarded as 
complementary in making a diagnosis of acute hepatitis E, especially if the sample for PCR 
testing is not addressed early enough. 
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Our study cannot provide any information on the incidence of hepatitis E in Switzerland. 
However, based on our data, the facts that hepatitis E is often diagnosed by serology alone 
and that other laboratories now also offer molecular testing, as well as the notion that most 
autochthonous HEV infections may occur in an asymptomatic or oligosymptomatic fashion, 
HEV is likely more frequent than hepatitis A, B or C viruses as a cause of acute hepatitis in 
Switzerland. Given the central location of Switzerland, our findings may apply also to other 
European countries. 
Interestingly, the majority of patients for whom this information was available did not recall 
any specific at-risk food consumption. Only a minority indicated the consumption of home-
made pork sausage, undercooked pork liver or raw game meat. 
Most cases of HEV infection acquired in Switzerland were found to be of genotype 3. 
However, we also identified three genotype 4 infections in patients who had not travelled to 
typical endemic regions for this genotype, i.e. China and Southeast Asia. Although scarce, 
isolated cases of autochthonous HEV genotype 4 infections have been reported in other 
European countries, including France, Italy, Germany and Denmark.26-28 The clinical course 
in our patients with HEV genotype 4 infection was particularly severe in one while the other 
two had moderate hepatitis without jaundice. 
The 191-195-bp fragment of the HEV ORF2/3 region amplified by our PCR assay is 
sufficient for assignment to each of the 4 main human pathogenic genotypes. However, this 
assay does not allow for reliable isolate distinction, as indicated by weak pb values (< 0.90) 
at specific nodes of the tree. A few limited geographial and temporal clusters according to 
Canton of residence and year of acute hepatitis E are nevertheless evident in our 
phylogenetic tree analysis. This clustering can be explained by the separation of certain 
regions of Switzerland, such as the Canton Ticino, by the Alps, a large mountain chain. 
ORF2-based genotyping with a larger DNA fragment has been reported to be more 
appropriate for subtyping.17, 18 We used a phylogenetic tree comparison method 
(Compare2Trees; ref. 29) to assess the prediction ability of the ORF2/3-based method 
described in this work and of the ORF2-based method. Using the reference tree built from 
the full-length genomes available in Genbank as of May 31, 2017, the ORF2-based method 
was not significantly superior to the ORF2/3-based method (topological scores of 80.7% and 
78.7%, respectively; P = 0.1204). We nevertheless reassessed HEV genotypes with the 
ORF2-based PCR. This assay was found to be less sensitive in our setting, allowing to 
successfully analyze the samples from 31 patients and confirming the limited clusters (data 
not shown). As also suggested by the ORF2/3-based genotyping method, ORF2-based 
phylogeny did not reveal any association of specific viral strains with defined clinical 
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outcomes. Of note, both genotyping methods taken together found the cases associated with 
neuralgic amyotrophy to be dispersed over the branches, with the exception of two cases 
from the Canton Ticino where geographical localization may explain the clustering. These 
findings are in line with a previous study which did not find any association of specific HEV 
genotype 3 variants and clinical manifestations.30 
Anti-HEV IgM were negative in 4 of 91 patients with available serology. Three of these 
were also IgG-negative, likely as a result of immunosuppression, and one was IgG positive, 
possibly reflecting reinfection. We confirm, therefore, that serologic assays are not reliable in 
the setting of immunosuppression and that molecular testing should be used in this situation. 
In line with previous studies,22, 31, 32 we found that middle-aged or elderly men represent 
the majority of patients presenting with symptomatic acute hepatitis E. Indeed, 3/4 of our 
patients were men and more than 2/3 of these were ≥ 50 years old. The reasons for this 
particular susceptibility remain currently unknown. 
Most patients in our series experienced self-limited hepatitis with a favorable outcome. 
However, HEV infection can cause significant morbidity and non-negligible mortality in 
patients with pre-existing chronic liver disease or due to extrahepatic, notably neurologic 
complications. A particularly severe course has been described in patients with underlying 
cirrhosis.22, 31, 33, 34 Two of the 93 patients (2.2%) in our series died as a consequence of 
acute HEV infection. Both had underlying cirrhosis and an initial diagnosis of alcoholic 
hepatitis had been made, motivating corticosteroid treatment in one. Ribavirin treatment was 
introduced in both patients once HEV infection was documented. However, the patients died 
shortly thereafter. Earlier diagnosis may have allowed to initiate ribavirin treatment more 
rapidly and successfully, as described in recent case series.35-37 Thus, testing for HEV 
infection should be considered in patients with presumed alcoholic hepatitis. 
Interestingly, several patients in our series spontaneously resolved acute hepatitis E 
despite immunosuppressive drug treatment, including 6 who were on corticosteroids. Only 
one of the latter had received high-dose corticosteroids in the course of acute hepatitis E 
while the others were treated with prednis(ol)one at doses of 10 to 20 mg per day. Hence, it 
appears, based on these few patients, that corticosteroids alone at low to moderate doses 
did not interfere with the patients' ability to eliminate HEV. 
Drug-induced liver injury is characterized by a wide range of both phenotype and severity. 
Diagnosis can be challenging and is generally based on chronological association between 
incriminated drug administration and liver injury. As previously reported,38, 39 acute hepatitis E 
was initially misinterpreted as drug-induced liver injury in at least two patients in our series. 
11 
Therefore, hepatitis E should be included in the differential diagnosis of drug-induced liver 
injury. 
Neurologic symptoms have been reported in retrospective studies in up to 5% of patients 
with HEV genotype 3 infection (reviewed in ref. 40). The hallmark neurological complication 
is neuralgic amyotrophy, and both immunological mechanisms as well as direct neurotropism 
have been discussed. In our study, 6 of 93 patients (6.5%) presented with neuralgic 
amyotrophy. They were men between 45 and 62 years (median 50 years) infected with 
genotype 3. Neurological manifestations have been reported in refs. 19 and 20. Most 
patients were treated with corticosteroids and/or intravenous immunoglobulines, according to 
local expertise. One patient was treated with prednisone and ribavirin 1000 mg per day, with 
negativation of HEV RNA within one week. Ribavirin treatment was pursued for 2 weeks after 
negativation of HEV RNA in plasma and stool, i.e. for a total of 3 weeks. Neuralgic pain 
resolved and muscle strength in the shoulder girdle improved rapidly; however, right-sided 
diaphragmatic paralysis persisted. Ribavirin treatment in the context of HEV-associated 
neuralgic amyotrophy requires further study. 
An inherent limitation of our study is the retrospective data collection. However, we were 
able to reach almost all practitioners throughout Switzerland to obtain demographic, clinical 
and laboratory data, and missing data were scarce. On the other hand, the multicentric data 
collection constitutes a strength of the study, reflecting "real-life" clinical experience with a 
majority of immune competent symptomatic patients. In addition, we restricted our study to 
PCR-documented cases of acute hepatitis E, thereby eliminating potential limitations related 
to the sensitivity and specificity of serological diagnosis. 
In conclusion, nucleic acid-based diagnosis reveals HEV as a relevant cause of acute 
hepatitis in Switzerland. Middle-aged and elderly men constitute the majority of symptomatic 
patients. Testing for HEV should be included early in the diagnostic workup of acute hepatitis 
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LEGENDS TO FIGURES 
FIG. 1. Analyses performed and patient disposition. (A) Number of HEV RNA analyses 
performed between 2011 and 2016. The number of positive samples is indicated in black. A 
total of 1981 samples were analyzed between 01.11.2011 and 31.12.2016, with 145 (7.3%) 
positive samples from 111 patients. (B) Disposition of the 110 patients with positive HEV 
RNA for whom clinical information was available. 
FIG. 2. Phylogenetic tree analysis. (A) Phylogenetic tree of 78 patient samples which could 
be successfully genotyped based on the 191-195-bp fragment of the HEV open reading 
frame 2/3 region and of 40 contig sequences representing the 310 full-length HEV genomes 
available in GenBank in September 2016. HEV genotype 2 was arbitrarily selected as 
outgroup. Nodes with a high posterior probability value (> 0.95) are indicated by an asterisk. 
Each sample is denoted by patient number, Canton of residence (using the same color code 
as in panel B) as well as year and month. The scale bar indicates the average number of 
substitutions per column of the alignment. (B) Map of Switzerland. The map was prepared 
using the tools available at http://d-maps.com. Samples from patients living in the following 
Cantons have been analyzed: AG, Aargau; BE, Berne; LU, Lucerne; NE, Neuchâtel; NW, 
Nidwalden; OW, Obwalden; SG, St. Gallen; SO, Solothurn; SZ, Schwyz; TI, Ticino; TG, 














Quantitative PCR. Total nucleic acids were purified from 200 µl plasma or serum 
supplemented with an internal RNA control with the MagNaPure 96 Total Nucleic Acids kit 
according to the manufacturer (Roche, Basel, Switzerland) and eluted in 100 µl elution 
buffer. Ten µl of the eluate was converted to cDNA in a 20-µl reaction (High Capacity cDNA 
Reverse Transcription Kit, Applied Biosystems, Foster City, CA), adjusted to 50 µl with PCR 
grade water, and 5 µl was subjected to real-time polymerase chain reaction according to 
Jothikumar N et al. (J Virol Methods 2006;131:65-71) with the updated primer set and 
reaction conditions listed in Supplementary Table 1. Each set of RNA extractions was 
accompanied by a negative water control to monitor contamination. 
Reaction conditions. For real-time PCR, the primers were ordered separately (Eurogentec, 
Seraing, Belgium) and mixed to 10 µM each as forward and reverse stocks in PCR grade 
water. The probe was also adjusted to 10 µM. The forward and reverse primers and the 
probe were then added at 200 nM each in a real-time PCR reaction mixture containing 10 µl 
2x TaqMan® Fast Universal PCR Master Mix (Applied Biosystems, Foster City, CA), 5 µl 
cDNA and PCR grade water to 20 µM final volume. Real-time PCR was performed in ABI 
instruments (ABI7900 and Quantstudio VI7) with the following cycling profile: 9 min at 95°C, 
followed by 50 cycles of 95°C for 1 sec and 60°C for 20 sec. HEV-negative results were valid 
only if the RNA internal control was positive at a similar Cp (crossing point) to the water-only 
extraction control. 
For ORF2/3-based genotyping, 2 µl cDNA was amplified with Amplitaq Gold (Applied 
Biosystems; 0.625 units) in a 25 µl mixture containing 1x Amplitaq Gold buffer, 3 mM MgCl2 
and 100 nM of each primer. The PCR profile was 95°C for 8 min, followed by 20 cycles of 
touch down PCR (94°C for 30 sec, touch down from 57°C to 47°C at 0.5°C reduction steps 
for 30 sec each, 72°C for 30 sec), followed by 25 cycles of conventional PCR (94°C for 30 
sec, 52°C for 30 sec and 72°C for 30 sec) and a final 5 min step at 72°C. Five µl PCR 
reaction was analyzed by gel electrophoresis. Positives were sequenced (each PCR primer) 
with Big Dye terminator chemistry and resolved on a 3130 XL instrument (Applied 
Biosystems). Sequences were then mapped against the HEV reference sequence. When the 
viral load was < 50,000 copies/ml plasma, it was preferable to treat the nucleic acid 
preparation with DNAse (Ambion, Thermo Fisher Scientific, Waltham, MA) prior to cDNA 
synthesis for successful genotyping PCR amplification. 
For ORF2-based genotyping, 2 µl cDNA was amplified with Amplitaq Gold Fast PCR 
Master Mix kit (Applied Biosystems) in a 25 µl mixture with either HEV-3156rs or HEV-
3162rs (to optimize coverage) and HEV-3159rs primers each at 800 nM according to the 
manufacturer. The PCR profile was 95°C for 8 min, followed by 20 cycles of touch down PCR 
(94°C for 30 sec, touch down from 60°C to 50°C at 0.5°C reduction steps for 30 sec each, 
72°C for 30 sec), followed by 25 cycles of conventional PCR (94°C for 30 sec, 52°C for 30 
sec and 72°C for 30 sec) and a final 5 min step at 72°C. Positives were sequenced as 
described for ORF2/3-based genotyping. 
Validation of the real-time PCR assay. As stated above, the real-time PCR assay was 
adapted from an already validated method described by Jothikumar N et al. (J Virol Methods 
2006;131:65-71), thus requiring less extensive validation. Analytical specificity was 100% 
using samples from patients presenting with hepatitis A, B, C or delta, as well as with human 
immunodeficiency virus. Sensitivity was assessed with cDNA positive controls; all reactions 
were positive with 100,000 and 1000 copies per reaction (n = 524 each) and 91% were 
positive with the 10 copies (n = 1060). Ten copies in a reaction translate to 375 HEV 
international units (IU) per ml of plasma. The average slope of the amplification plots 
(n = 524) was −3.56 (PCR efficiency of 91%). Participation in the Quality Control for 
Molecular Diagnosis (http://www.qcmd.org) from 2013 to 2016 was successful for all core 
2 
samples (n = 24, mostly genotype 3) and in 5 of 8 educational samples containing low viral 
loads close to our limit of detection of 375 IU/ml of plasma. 
 
Supplementary Table 1. Primers and probes used for molecular assays. 
 
 Name Sequence (5'-3') 
JVRSHEV_F1 (5310) CGGTGGTTTCTGGGGTGAC 
JVRSHEV_F2 GCAGTGGTTTCTGGGGTGAC 
JVRSHEV_F3 GCGGTGGTTTCTGGAGTGAC 




JVRSHEV_R2 (5382) GAAGGGGTTGGTTGGATGAA 
JVRSHEV_R3 CGAAAGGGTTGGTTGGATGAA 
JVRSHEV_R4 AAGGGGTTGGCTGGATGAA 
Reverse primers for 
real-time PCR 
JVRSHEV_R5 CGAAGGGATTGGTTGGATGAA 
Probe for real-time 
PCR 
JVRSHEV_Pt (5336) FAM-ATTCTCAG+C+C+CYTYGC-BHQ1 
ORF2/3 forward 
primer for genotyping 
HEVgenF-H (5152) GGGTGGAATGAATAACATGT 
ORF2/3 reverse 
primer for genotyping 
HEVgenR-A (5379) GGGGTTGGTTGGATGAA 
ORF2 forward primer 
for genotyping 
HEV-3156rs (5734) TCCAATTATGCCCAGTATCGGGT 
Alternative ORF2 
forward primer for 
genotyping 
HEV-3162rs (5638) GCTTCGGGTACTAATTTGGT 
ORF2 reverse primer 
for genotyping 
HEV-3159rs (6368) ACAGAATTGATTTCGTCGGC 
 
Numbers in parentheses indicate the position of the 5’ end relative to the reference sequence 
(GenBank accession number AF060669). 
+C denotes locked nucleic acids used to increase the Tm of the probe. BHQ, black hole 
quencher; FAM, 6-carboxyfluorescein. 
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Supplementary Table 2. Clinical characteristics of 93 patients with acute hepatitis E 
documented by PCR for HEV RNA. 
 



























1 m 69 2.6E+04 3 n n n 1238 n pos pos   
2 f 56 1.2E+06 3 n n n 1322 y (187) pos neg   
3 m 64 6.2E+03 3 n n n n.a. y (141) pos pos   
4 m 75 8.3E+03 3 n y n 1200 y (69) pos pos Prednisolone 15 mg qd for RA 
5 m 71 5.2E+04 3 n n n 793 y pos pos   
6 m 72 5.6E+04 3 n n n 260 n pos pos   
7 m 56 3.9E+06 3 n n n 2000 n pos pos   
8 m 60 2.0E+05 3 y n y 1500 y (406) pos pos  
9 m 67 2.6E+03 n.a. y y n 950 y pos pos Erlotinib for lung cancer 




11 m 46 6.3E+01 3 n n n 400 n pos pos   
12 f 37 5.6E+03 3 n y n n.a.  n pos pos Pulmonary transplant recipient 
13 m 33 1.5E+05 3 n n n 1486 y (190) pos pos   
14 m 52 4.4E+05 3 n n y 2579 n pos neg   
15 m 42 7.5E+05 3 n n n 3500 y (122) pos pos   
16 m 46 8.3E+04 3 n n n 4660 y (244) pos pos   
17 m 41 2.1E+07 3 n y n 3403 n neg neg 
Lymphoma treated 
with R-CHOP 7 
months earlier 
18 m 71 5.3E+01 n.a. n n n 663 n pos pos   
19 m 53 2.2E+05 3 n n n 3552 y (157) n.a. n.a.   
20 m 50 9.8E+03 3 n n n 753 n pos pos   
21 m 73 4.2E+03 3 y y n 344 y (76) pos pos Rituximab for lymphoma 
22 m 73 7.5E+02 n.a. n n n 750 y (77) pos pos   
23 m 72 5.3E+00 n.a. n y n n.a. y (228) neg neg 
Prednisone 20 mg 
qd for pulmonary 
fibrosis 
24 f 41 4.0E+04 3 n n n 500 n pos pos   
25 m 44 1.7E+06 3 n n n 2549 n pos n.a.    
26 m 29 1.1E+04 3 n n n 232 n pos pos   
27 m 52 7.0E+03 3 n n n n.a. y (150) pos pos   
28 m 42 7.5E+04 3 n n n 2000 y (80) pos pos   
29 f 31 9.0E+04 3 n n n 1734 n pos pos   
30 m 67 2.5E+05 3 n n n n.a. n pos pos   
31 m 44 5.6E+04 3 n n n 510 y pos pos   
32 m 55 1.3E+04 3 n n n n.a. n pos pos Severe myalgia 
33 m 52 3.5E+07 3 n n n n.a. y pos pos Severe myalgia 
34 f 51 1.6E+05 3 n n n 1825 n pos pos   
35 m 62 2.8E+04 3 n n y n.a. n pos pos   
36 m 46 4.8E+05 3 n n n 3193 n pos pos   
37 m 65 1.1E+04 3 n y n 664 n pos pos Methotrexate for RA 
38 m 64 3.5E+05 3 n n n 1270 n pos pos   
39 f 71 4.8E+05 n.a. n n n 984 n pos pos   
40 f 67 2.9E+03 3 n n n  n.a. n pos pos   
41 f 46 2.5E+04 n.a. n n n 537 y pos pos Severe myalgia 
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42 m 50 5.0E+05 3 n n n 3028 y (79) pos pos   
43 m 80 2.2E+03 3 y n n 2600 y (602) pos pos Acute-on-chronic liver failure 
44 f 67 6.8E+03 n.a. n y n 700 y pos pos Methotrexate for RA 
45 f 80 9.0E+04 3 n n n 1215 y (195) pos pos   
46 m 62 9.8E+06 3 n n y 2462 y (69) pos pos   
47 m 45 2.0E+04 3 n n y 99 n pos pos   
48 f 37 4.5E+04 3 n n n 900 y (76) pos pos   
49 m 49 9.8E+04 n.a. n n n 1560 n pos pos   
50 m 43 4.8E+05 3 n n n 4000 y (90) pos pos   
51 m 40 6.1E+05 3 n n n 1300 y (60) pos pos   
52 f 52 2.3E+05 3 n y n 1656 y (170) pos pos Prednisolone for Takayasu arteriitis 
53 m 74 8.3E+03 n.a. y n n 705 y (458) pos pos Acute-on-chronic liver failure 
54 m 48 3.9E+04 3 n n n 1800 y (77) pos pos   
55 m 45 3.3E+04 3 n n n 2500 y (160) pos pos   
56 f 48 2.4E+04 n.a. n n n 947 n pos pos   
57 m 75 9.0E+04 3 n n n 1445 y (196) pos pos   




59 m 75 1.5E+05 3 n n n 3353 y (71) pos neg   
60 m 59 2.7E+06 3 n n n 1882 n pos neg   
61 m 63 2.3E+05 3 n y n 600 n pos pos Renal transplant recipient 
62 m 20 1.5E+04 3 n n n 4000 y (270) pos pos   
63 f 75 3.7E+04 3 n n n 3463 y (46) pos pos   
64 m 72 4.8E+05 3 y n n 809 y (189) pos pos  
65 m 62 7.5E+04 3 n n n 440 y pos pos   
66 f 64 9.8E+04 3 n y n  n.a. y pos pos Osteomyelofibrosis 
67 m 45 1.7E+05 3 n n n 5001 y (45) pos pos   
68 m 49 1.1E+05 3 n n y 1111 n pos pos   
69 m 73 6.5E+05 3 n n n 1500 y (97) pos pos   
70 m 57 1.7E+03 n.a. n n n 1947 n pos pos Severe myalgia 
71 m 71 3.6E+05 3 n n n 488 y (162) pos pos   
72 m 61 4.2E+05 3 n n n 1849 n pos pos   
73 m 67 2.2E+04 3 n n n 1404 y (93) pos pos   
74 m 33 9.8E+04 n.a. n n n 1110 y (46) n.a. n.a.   
75 m 72 1.1E+07 3 n y n 478 n pos pos Renal transplant recipient 




77 m 62 1.7E+04 3 n n n 2192 n pos pos   
78 m 88 7.5E+05 3 n y n 1500 n pos pos 
Methylprednisolone 
and mycophenolate 
for minimal change 
disease 
79 m 49 3.8E+04 3 n n n 2000 y (101) pos pos   
80 f 47 1.5E+04 3 n n n 1672 n pos pos   
81 m 46 2.2E+07 3 n n n 1100 y (55) pos neg   
82 f 54 4.7E+07 3 n y n 521 n neg neg Renal transplant recipient 
83 f 47 1.4E+03 n.a. n y n 805 n pos neg Chemotherapy for breast cancer 
84 m 74 5.3E+06 3 n n n 1500 y (120) pos pos   
85 f 53 1.1E+04 n.a. n n n 390 n pos pos Severe myalgia 
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86 m 76 2.3E+05 3 n n n 2985 y (86) pos pos   
87 m 53 2.2E+04 3 n n n 1352 n pos pos   
88 f 63 2.9E+05 3 n n n 1476 n pos pos   
89 m 77 1.4E+06 3 n n n 800 n pos pos   
90 m 64 2.8E+06 3 n n n 2456 y (72) pos neg   
91 m 59 5.2E+04 4 n n n 2450 y (256) pos pos 
Severe course in 
the absence of pre-
existing cirrhosis 
92 m 62 1.2E+03 4 n n n 80 n pos pos   
93 m 62 4.6E+02 4 n n n 591 n neg pos   
 
*Peak total bilirubin levels in patients with jaundice are given in parentheses in µmol/l. 
ALT, alanine aminotransferase; HEV, hepatitis E virus; n, no; n.a., not available; NA, 
neuralgic amyotrophy; neg, negative; Pat., patient; pos, positive; RA, rheumatoid arthritis; 
SLE, systemic lupus erythematosus; y, yes. 
